Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BAX 
Baxter International Inc (BAX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/12/2025: BAX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
18 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $24.07
1 Year Target Price $24.07
| 4 | Strong Buy |
| 2 | Buy |
| 11 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -2.94% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/12/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 9.38B USD | Price to earnings Ratio - | 1Y Target Price 24.07 |
Price to earnings Ratio - | 1Y Target Price 24.07 | ||
Volume (30-day avg) 18 | Beta 0.61 | 52 Weeks Range 17.47 - 37.27 | Updated Date 11/11/2025 |
52 Weeks Range 17.47 - 37.27 | Updated Date 11/11/2025 | ||
Dividends yield (FY) 3.83% | Basic EPS (TTM) -0.7 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-10-30 | When - | Estimate 0.5964 | Actual 0.69 |
Profitability
Profit Margin -3.09% | Operating Margin (TTM) 10.12% |
Management Effectiveness
Return on Assets (TTM) 2.85% | Return on Equity (TTM) -4.66% |
Valuation
Trailing PE - | Forward PE 7.56 | Enterprise Value 17110490538 | Price to Sales(TTM) 0.85 |
Enterprise Value 17110490538 | Price to Sales(TTM) 0.85 | ||
Enterprise Value to Revenue 1.55 | Enterprise Value to EBITDA 16.5 | Shares Outstanding 514055805 | Shares Floating 511896771 |
Shares Outstanding 514055805 | Shares Floating 511896771 | ||
Percent Insiders 0.37 | Percent Institutions 101.44 |
Upturn AI SWOT
Baxter International Inc
Company Overview
History and Background
Baxter International Inc. was founded in 1931 as Don Baxter Intravenous Products Corporation. It pioneered the development of commercially prepared intravenous solutions. Over the decades, it expanded into various areas of healthcare, including renal care, medication delivery, and advanced surgery products.
Core Business Areas
- Medical Products and Therapies: Includes IV solutions, drug delivery systems, renal care products, advanced surgery products, and other medical devices used in hospitals and clinics. Focuses on providing a broad range of essential healthcare products.
- Renal Care: Offers products and services for patients with kidney disease, including dialysis systems, dialyzers, and related solutions for home and in-center dialysis. This segment includes equipment, solutions and services for peritoneal and hemodialysis.
Leadership and Structure
Baxter is led by Josu00e9 (Joe) E. Almeida as Chairman, President, and Chief Executive Officer. The company operates with a global structure, organized into business units focused on specific therapeutic areas. It has a hierarchical management structure with regional and functional leadership teams.
Top Products and Market Share
Key Offerings
- IV Solutions: Baxter is a major player in the intravenous (IV) solutions market, providing a range of solutions for hydration, medication delivery, and nutrient administration. The market is competitive, with companies like B. Braun (BBRNF), Fresenius Kabi (FMS), and ICU Medical (ICUI) as competitors. Market share is estimated to be ~25% in the global IV solutions market.
- Dialysis Products: Baxter offers a comprehensive portfolio of dialysis products, including hemodialysis and peritoneal dialysis systems. These products are vital for patients with end-stage renal disease. Key competitors in the dialysis market are Fresenius Medical Care (FMS) and DaVita (DVA). Baxter has a ~20% market share in the dialysis product space.
- Advanced Surgery Products: Baxter offers bio-surgical products and sealants used in surgery to control bleeding and aid in tissue repair. Competitors include Johnson & Johnson (JNJ), Medtronic (MDT), and Stryker (SYK). Revenue generated from this segment is in the hundreds of millions of USD annually. Baxter leads the market and estimates its market share at ~22%.
Market Dynamics
Industry Overview
The healthcare industry is experiencing growth driven by an aging population, increasing prevalence of chronic diseases, and advancements in medical technology. The industry is subject to stringent regulatory requirements and intense competition.
Positioning
Baxter is a well-established player in the healthcare industry with a strong brand reputation and a diverse product portfolio. Its competitive advantages include its global reach, extensive distribution network, and focus on innovation.
Total Addressable Market (TAM)
The global medical device market is expected to reach $600+ billion by 2030. Baxter is positioned to capture a portion of this TAM through its diverse product lines and continued investment in R&D.
Upturn SWOT Analysis
Strengths
- Strong brand reputation
- Diverse product portfolio
- Global reach
- Extensive distribution network
- Commitment to innovation
Weaknesses
- Exposure to currency fluctuations
- Product recalls can be costly
- Dependence on hospital spending
- Increased competition in certain segments
- High debt level
Opportunities
- Expanding into emerging markets
- Developing new products and therapies
- Acquiring complementary businesses
- Leveraging digital technologies
- Strategic partnerships
Threats
- Intense competition
- Pricing pressures
- Regulatory changes
- Economic downturns
- Technological obsolescence
Competitors and Market Share
Key Competitors
- Fresenius Medical Care (FMS)
- Becton, Dickinson and Company (BDX)
- Medtronic (MDT)
- Johnson & Johnson (JNJ)
Competitive Landscape
Baxter faces intense competition from large, well-established players in the healthcare industry. It competes on product innovation, quality, price, and customer service. Baxter's strong brand reputation and global reach provide a competitive advantage.
Major Acquisitions
Hillrom
- Year: 2021
- Acquisition Price (USD millions): 12400
- Strategic Rationale: Expanded Baxter's connected care solutions and patient monitoring capabilities, diversifying its product portfolio and creating synergy within hospital settings.
Growth Trajectory and Initiatives
Historical Growth: Baxter's growth has been moderate over the past several years, with revenue growth driven by acquisitions and new product launches.
Future Projections: Analysts project moderate revenue growth for Baxter in the coming years, driven by increasing demand for its products and services. The company's focus on innovation and emerging markets is expected to contribute to future growth.
Recent Initiatives: Baxter has undertaken several strategic initiatives, including cost-cutting measures, portfolio optimization, and investments in digital technologies.
Summary
Baxter International is a global healthcare company with a diverse portfolio of medical products and services, but faces challenges. Its strengths lie in its established brand and wide range of products. However, the company has profitability challenges, with a negative income, and a high debt load. It should focus on cost-cutting and innovation to improve performance.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC filings
- Analyst reports
- Industry publications
- Company investor relations materials
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Market share data are estimates and may vary depending on the source. Financial data are based on publicly available information and may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Baxter International Inc
Exchange NYSE | Headquaters Deerfield, IL, United States | ||
IPO Launch date 1981-10-27 | CEO, President, Interim Group President of Medical Products & Therapies and Director Mr. Andrew P. Hider | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 38000 | Website https://www.baxter.com |
Full time employees 38000 | Website https://www.baxter.com | ||
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; administrative sets; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It has an agreement with Celerity Pharmaceuticals, LLC to develop acute care generic injectable premix and oncolytic products. The company operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.